HWM
CRSP icon

HighMark Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

HighMark Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10
Closed -$486 – 623
2025
Q2 		$486 Hold
10
– – ﹤0.01% 563
2025
Q1 		$340 Hold
10
– – ﹤0.01% 536
2024
Q4 		$394 Hold
10
– – ﹤0.01% 539
2024
Q3 		$470 Hold
10
– – ﹤0.01% 546
2024
Q2 		$540 Sell
10
-315
-97% -$18.2K ﹤0.01% 532
2024
Q1 		$22.2K Buy
+325
New +$23.3K 0.01% 188
2022
Q4 		– Sell
-275
Closed -$18K – 548
2022
Q3 		$18K Buy
+275
New +$19.9K 0.02% 173

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

HighMark Wealth Management's CRSP Position: Q3 2025 in Review

HighMark Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 10 shares — an estimated $486 sold.

HighMark Wealth Management first reported a position in CRSP in Q3 2022 and held it in 7 quarters. The position peaked at $22.2K in Q1 2024. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • HighMark Wealth Management reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HighMark Wealth Management sold 10 CRISPR Therapeutics shares in Q3 2025, an estimated $486.
  • HighMark Wealth Management first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 7 quarters.
  • HighMark Wealth Management's CRISPR Therapeutics position peaked at $22.2K in Q1 2024.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on HighMark Wealth Management's 13F filing for Q3 2025, filed 20 Oct 2025.